Resurfacing a July move: Mounjaro topped ₹50 crore in India sales as Wegovy entered obesity-drug race
As of early July 2025, Eli Lilly’s Mounjaro had crossed ₹50 crore in sales since its March India launch, including ₹26.3 crore in June. Novo Nordisk’s Wegovy recorded ₹2.53 crore in sales in its first two weeks, underscoring rapid growth in India’s ₹628 crore anti-obesity market.
What happened
Eli Lilly’s Mounjaro has exceeded ₹50 crore in Indian sales since its March launch, while Novo Nordisk’s Wegovy generated ₹2.53 crore in two weeks. The ₹628
Key facts
- Indian anti-obesity market: ₹628 crore
- Mounjaro total sales since launch: over ₹50 crore
- Mounjaro June sales: ₹26.3 crore
- Wegovy sales: ₹2.53 crore in two weeks
- Wegovy secondary sales: 1,788 units
What changed
Eli Lilly’s Mounjaro has exceeded ₹50 crore in Indian sales since its March launch, while Novo Nordisk’s Wegovy generated ₹2.53 crore in two weeks. The ₹628 crore anti-obesity market is expanding rapidly as both companies add convenient delivery formats.
Why this matters
Mounjaro’s rapid ₹50 crore sales milestone and Wegovy’s fast start signal a high-growth consumer-health category that pharmacies, clinics and wellness retailers should prepare to serve with education and adherence support.
What to watch
- Monthly audited anti-obesity drug sales remain above 15-20% growth after initial launch stocking.
- Mounjaro refill and dose-escalation data indicate sustained use rather than one-month experimentation.
- Wegovy gains broad stock availability across metro pharmacies and closes the early sales gap with Mounjaro.
- Private insurers, employers or hospital networks introduce obesity-treatment reimbursement or financing plans.
- Indian regulators approve additional GLP-1 agents, oral options, or domestic alternatives that reduce treatment costs.